Efpeglenatide record · updated 18h ago

Metabolic & appetiteHealing & recoveryGrade A · human clinicalResearch use only

All 6 studies Jump to the evidence Compare

What is Efpeglenatide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: GLP-1 receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Efpeglenatide sits between preclinical work and regulatory approval

1Current
Preclinical
Animal / in-vitro work
2Not reached
Phase 1
Safety in humans
3Not reached
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 19 registered trials. It describes the research record, not a recommendation.

Identity

NameEfpeglenatide

Chain length—

Molecular weight—

Formula—

Structure type—

ClassMetabolic

Research levelExtensively Studied

Discovered byThe Librarian · 2026

Pharmacology

MechanismGLP-1 receptor agonist

RouteSubcutaneous injection

Half-life—

Time to peak—

Duration—

Extraction confidence0.80

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 9, 2026. How this works →

Research stats

Total studies6

Human / animal / cellular4 / 0 / 0

Highest trial phase—

Years covered2023–2026

Latest study8d ago

Publication history

20232026

Research funding

—no NIH grants found

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 6 Semantic Scholar UniProt

Study register

6 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
Perioperative Administration of Efgartigimod in myasthenia gravis patients with Thymoma: A six-case series. FindingNot reported in abstract.	Human	2026	Full text read0.70
Durable platelet response and immature platelet indices following sequential efgartigimod and eltrombopag therapy in a patient with refractory ITP. FindingNot reported in abstract.	Human	2026	Full text read0.80
Cost comparison of intravenous immunoglobulin and subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy. Finding$124,812 total treatment cost for Panzyga 1 g/kg at 6 months.	review	2026	Full text read0.70
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. FindingMACE occurred in 125 (9.2%) participants assigned to placebo, 84 (6.2%) participants assigned to 6 mg of efpeglenatide, HR 0.65 (95% CI, 0.5-0.86), P=0.0027.	Human	2023	Full text read0.90
The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis. FindingNot reported in abstract.	review	2026	Full text read0.80
Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial. Finding27% reduction in major cardiovascular events compared to placebo during a median follow-up of 1.81 years, n=4076.	Human	2026	Full text read0.90

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Efpeglenatide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Efpeglenatide is discussed should be drawn from it.